Möchten Sie immer auf dem neuesten Stand bleiben?

Gotistobart zeigte einen klinisch relevanten Gesamtüberlebensvorteil im Vergleich zur Standard-Chemotherapie und ein kontrollierbares Sicherheitsprofil

Gotistobart demonstrated a clinically meaningful overall survival benefit compared to standard chemotherapy and a manageable safety profile in sqNSCLC

CHICAGO, Dec. 01, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted...

Immuneering to Present at the Piper Sandler 37th Annual Healthcare Conference

LOUISVILLE, Ky., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Onco360®, the nation’s leading independent Specialty Pharmacy, has been selected as the national pharmacy partner by Bayer Pharmaceuticals for...

Ingelheim, Germany / Ridgefield, Connecticut, U.S. Data from the Phase Ib Beamion LUNG-1 trial evaluating zongertinib in treatment-naïve patients with advanced HER2 (ERBB2)-mutant NSCLC were...

Monotherapy shows deep and durable responses in NSCLC and a best-in-class safety profile without thrombocytopeniaCompletion of monotherapy dose escalation part of the study will be followed by the...

FDA has approved Junshi Biosciences' IND for a Phase 2/3 clinical study of JS207 (PD-1/VEGF), for the neoadjuvant treatment of NSCLC

$50 million drawn down at closing, with access to up to an additional $80 millionStrengthens Company’s financial position; enables initiation of phase 3 clinical trial of CAN-2409 in non-small cell...

Immuneering Announces Pricing of $175 Million Underwritten Public Offering of Class A Common Stock and Concurrent $25 Million Private Placement of Class A